Drug Discovery Featured Articles & Applications

1. TYK2 Inhibition Emerges As A Next-Gen Strategy To Treat PsA 7/10/2025

   The treatment landscape for psoriatic arthritis (PsA) is evolving rapidly, with data presented at EULAR 2025 signaling a new chapter in disease management with the emergence of a selective tyrosine kinase 2 (TYK2) inhibitor.

2. Multi-Indication Strategies Reshape Immunology's R&D Strategy 7/10/2025

   A clear trend at EULAR 2025 emerged across presentations and pipelines: leading biopharma players are increasingly embracing multi-indication strategies, designing assets to work across dermatology, rheumatology, and gastroenterology indications.

3. Immunology's Next Frontier: High-Risk, High-Reward Innovations From EULAR 2025 7/10/2025

   The 2025 European Congress of Rheumatology (EULAR) showcased a shift in immunology, highlighting a convergence of next-generation mechanisms and novel therapeutic modalities. Of note is the emergence of cell therapies as a treatment strategy.

4. New Regulatory Considerations For Animal Testing And The Consequences For Drug Product Formulation Development 7/3/2025

   The U.S. is experiencing a shift in the regulatory environment for animal testing, driven by the evolving use of AI. This impacts the formulation development approach for new drugs in the non-clinical phase. 

5. From Undruggable To Druggable: The Science Reshaping Small Molecule Discovery 7/1/2025

   For decades, most biologically validated disease-relevant protein targets have remained chemically inaccessible, thereby resisting conventional small molecule approaches. But now, a new wave of scientific innovation is paving a way forward.

6. Five Takeaways from BIO 2025 and Why You Should Stay Tuned 6/26/2025

   New chief editor of Drug Discovery Online shares insights from BIO 2025’s global biotech gathering and spotlights the impacts to early-stage drug research.

7. From Matrix To Medicine: New Frontiers In Treating Pulmonary Fibrosis And PH 6/25/2025

   Halo Biosciences is building a pipeline based on novel insights into how extracellular matrix dysregulation drives disease. We caught up with its leaders to discuss their approach to drug targeting and early development.

8. Tackling Antimicrobial Resistance With Precision Targeting 6/20/2025

   TAXIS Pharmaceuticals is developing therapies to combat antimicrobial resistance. We caught up with the company's CEO and CSO to discuss their approach to early R&D.

9. Formulation Development Of A JAK1 Inhibitor Extended-Release Tablet 6/19/2025

   This scientific article presents a summary of the formulation development strategy of a JAK1 inhibitor extended-release tablet, with a focus on experimental design, data interpretation, and formulation decision-making.

10. A Guide To Designing mRNA Medicines 6/10/2025

    A poorly designed mRNA sequence can create ongoing difficulties during downstream clinical development and manufacture. Let's take a closer look at strategies and design software that you can employ.